Diroximel fumarate · Vumerity
Small molecule
Also known as ALKS 8700
Evidence outlook
Approved: Multiple Sclerosis (label: adults; clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Adult patients with relapsing remitting multiple sclerosis
- Relapsing-remitting multiple sclerosis (diroximel fumarate / Vumerity)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05083923 NCT05083923 · Relapsing Forms of Multiple Sclerosis The study was a single-group, open-label trial with 136 participants enrolled and no placebo or active comparator. Its primary outcomes were safety measures rather than a comparative clinical efficacy endpoint, so there was no formal primary treatment comparison to meet or miss; the reported safety findings are descriptive only. Registry: NCT05083923 | 3 | Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) (Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)); Part 1: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters (Baseline (Day 1) to Week 24); Part 1: Number of Participants With Abnormal Shift in 12-Lead Electrocardiogram (ECG) Values (Baseline (Day 1) to Week 24); Part 1: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters (Baseline (Day 1) to Week 24); Part 1: Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Events (Baseline (Day 1) to Week 24); Parts 1 and 2: Number of Participants With TEAEs and TESAEs (From Day 1 up to the end of the study (up to Week 50)); Part 2: Number of Participants With Potentially Clinically Significant Abnormalities in Laboratory Parameters (Baseline (Day 1) to Week 48); Part 2: Number of Participants With Abnormal Shift in 12-Lead ECG Values (Baseline (Day 1) to Week 48); Part 2: Number of Participants With Clinically Relevant Abnormalities in Vital Sign Parameters (Baseline (Day 1) to Week 48); Part 2: Number of Participants With C-SSRS Events (Baseline (Day 1) to Week 48) 2024-09-11 | Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) (Baseline (Day 1) up to Week 24 (for prematurely discontinued participants, AEs were reported up to 2 weeks post discontinuation)): Cohort 1: Japanese Participants — TEAEs: 50 Participants; TESAEs: 3 Participants | Cohort 2: Chinese Participants — TEAEs: 45 Participants; TESAEs: 5 Participants | Weak signal | link ↗ |
View 3 more trials
NCT02634307 NCT02634307 · Multiple Sclerosis The study was a single-group, open-label trial with no placebo or active comparator, although it included 464 participants who rolled over from ALK870-A302. Its primary outcomes were safety measures rather than a controlled clinical efficacy comparison, so the findings provide limited evidence for treatment effectiveness. Registry: NCT02634307 | 3 | Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose to two weeks after last dose of study drug (Up to 98 weeks)); Number of Participants With Potentially Clinically Significant Vital Sign Abnormalities (From first dose to two weeks after last dose of study drug (Up to 98 weeks)); Number of Participants With Potentially Clinically Significant 12-Lead Electrocardiogram (ECG) Abnormalities (From first dose to two weeks after last dose of study drug (Up to 98 weeks)); Number of Participants With Columbia Suicide Severity Rating Scale (C-SSRS) Score at Any Post-Baseline Visit (Up to 98 weeks); Number of Participants With Potentially Clinically Significant Laboratory Abnormalities (From first dose to two weeks after last dose of study drug (Up to 98 weeks)) 2021-06-01 | Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (From first dose to two weeks after last dose of study drug (Up to 98 weeks)): De Novo — TEAEs: 519 Participants; SAEs: 69 Participants | Rollover: ALKS 8700 — TEAEs: 212 Participants; SAEs: 29 Participants | Rollover: DMF — TEAEs: 207 Participants; SAEs: 25 Participants | Weak signal | link ↗ |
NCT03093324 NCT03093324 · Relapsing Remitting Multiple Sclerosis The trial randomized 504 participants to ALKS 8700 or active-controlled dimethyl fumarate and used quadruple blinding with matching placebo capsules. Its primary endpoint, a patient-reported gastrointestinal symptom measure, was significantly better with ALKS 8700 (p=0.0003), but this was a short-term symptom/tolerability endpoint rather than a hard clinical or endoscopic measure. Registry: NCT03093324 | 3 | Number of Days With Any Individual Gastrointestinal Symptom and Impact Scale (IGISIS) Individual Symptom Intensity Score ≥2 Relative to Exposure Days in Parts A and B (End of treatment (up to Week 6) for both Parts A and B) 2019-06-27 | Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. | Partial signal | link ↗ |
VOYAGE NCT07483632 · Relapsing Forms of Multiple Sclerosis Registry: NCT07483632 | 3 | TP Cohort A and OLE Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and AEs Leading to Treatment Discontinuation (Cohort A: From first dose of study drug up to end of follow-up (up to Week 104), OLE: Baseline (Week 96) up to the end of OLE period (up to Week 196)); TP Cohort B: Annualized Relapse Rate (ARR) Through Week 96 (Baseline (Day 1) up to Week 96) 2034-07-28 | In progress: results expected 28 Jul 2034 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 1 (1)
What this study did
Competitive landscape
Other Nrf2 pathway (fumaric acid ester) drugs
Bafiertam, Dimethyl fumarate (Tecfidera), Dimethyl fumarate (Skilarence). Compare all 4 Nrf2 pathway (fumaric acid ester) drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Multiple Sclerosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Diroximel Fumarate (Vumerity): this drug | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | Weak signal | NCT03093324: Primary GI symptom days: mean 1.5 (SD 2.85) with ALKS 8700 vs 2.5 (SD 4.68) with dimethyl fumarate; rate ratio 0.542 (95% CI 0.390-0.754), p=0.0003. | |
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | Partial signal | NCT00930553: Annualized Relapse Rate (ARR) (Year 3, 4, 5, 6 from the Baseline (Month 0 of CAMMS323 and Month 0 of CAMMS324 for "Alemtuzumab Treatment CAMMS323 Extension" group and "Alemtuzumab Treatment CAMMS324 Extension" group, respectively)): Alemtuzumab Treatment CAMMS323 Extension — Year 3: 0.19 relapses per participant per year; Year 4: 0.16 relapses per participant per year; Year 5: 0.15 relapses per participant per year; Year 6: 0.12 relapses per participant per year | Alemtuzumab Treatment CAMMS324 Extension — Year 3: 0.22 relapses per participant per year; Year 4: 0.24 relapses per participant per year; Year 5: 0.19 relapses per participant per year; Year 6: 0.16 relapses per participant per year NCT00548405: Percentage of Participants With Sustained Accumulation of Disability (SAD) (Up to 2 years): Alemtuzumab 12 mg 12.71% (95% CI 9.89 to 16.27) vs Interferon Beta-1a 21.13% (95% CI 15.95 to 27.68) | |
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | not yet graded | No reviewed efficacy summary in this indication | |
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | Reliable signal | NCT00213135: Annualized Qualifying Relapse Rate (Week 96): Cladribine 5.25 mg/kg 0.15 relapses per year (95% CI 0.12 to 0.17) | Cladribine 3.5 mg/kg 0.14 relapses per year (95% CI 0.12 to 0.17) vs Placebo 0.33 relapses per year (95% CI 0.29 to 0.38) | |
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | not yet graded | No reviewed efficacy summary in this indication | |
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | Reliable signal | NCT00451451: Adjusted annualized relapse rate at 2 years: 0.224 relapses/year (95% CI 0.179–0.282) with BG00012 240 mg BID vs 0.401 (95% CI 0.329–0.488) with placebo; 0.198 (95% CI 0.156–0.252) with BG00012 240 mg TID vs 0.401 (95% CI 0.329–0.488) with placebo. NCT00420212: Estimated proportion relapsed by 2 years: 27% with BG-12 240 mg twice daily and 26% with 240 mg three times daily vs 46% with placebo (P<0.001 for both comparisons) (DEFINE, N Engl J Med 2012). | |
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | Partial signal | NCT00127530: Timed walk responders: fampridine 78/224 (35%) vs placebo 6/72 (8%), p<0.0001 (Goodman et al., Lancet 2009) | |
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | Reliable signal | NCT00289978: Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) NCT00340834: Annualized relapse rate over 12 months: fingolimod 1.25 mg 0.20 (95% CI 0.16 to 0.26) and 0.5 mg 0.16 (95% CI 0.12 to 0.21) vs interferon beta-1a IM 0.33 (95% CI 0.26 to 0.42); p<0.001 for both comparisons. n=1,292 randomized (TRANSFORMS, Cohen 2010, NEJM). | |
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | Weak signal | NCT00211887: ARR - PDEs (Baseline to Month 36): IFN + GA 0.12 relapses per year | IFB-1a 0.16 relapses per year vs Glatiramer 0.11 relapses per year | |
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Partial signal | NCT00185211: Time to Clinically Definite Multiple Sclerosis (CDMS) Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS at Selected Points in Time (up to 60 months after start of treatment): Initial IFNB-1b (Interferon Beta-1b) — Kaplan-Meier estimate at year 2: 26.9 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 36.7 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 46.2 cum. percentage of particip. with CDMS vs Initial Placebo — Kaplan-Meier estimate at year 2: 45 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 3: 51.2 cum. percentage of particip. with CDMS; Kaplan-Meier estimate at year 5: 57.3 cum. percentage of particip. with CDMS NCT00099502: Enrolled 897 (250mcg) + 899 (500mcg) + 448 (glatiramer acetate) = 2244 patients (matches this trial's enrollment). Annualized relapse rate 0.33-0.36 across arms; no statistically significant difference in relapse/progression measures between the 500mcg and 250mcg IFN beta-1b doses, or vs glatiramer acetate. missed | |
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | Reliable signal | NCT00027300: Sustained disability progression at 2 years reduced 42% (hazard ratio 0.58, 95% CI 0.43-0.77, P<0.001; cumulative probability 17% natalizumab vs 29% placebo); clinical relapse rate at 1 year reduced 68% (P<0.001). NCT03689972: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 (Week 72): Part 1: IV Q4W 0.05 number of T2 lesions (95% CI 0.01 to 0.22) | Part 1: IV Q6W 0.2 number of T2 lesions (95% CI 0.07 to 0.63) | |
| Ocrelizumab | Approved | Monoclonal antibody | CD20 | Partial signal | NCT05123703: Protocol-defined annualized relapse rate: ocrelizumab 0.070 vs fingolimod 0.135; adjusted rate ratio 0.517 (95% CI 0.193 to 1.329), non-inferiority analysis (CT.gov posted results); Roche states non-inferiority to fingolimod with a 48% lower relapse risk. NCT01247324: Annualized Relapse Rate (ARR) in Participants With Relapsing Multiple Sclerosis (MS) at 96 Weeks (Week 96): Interferon Beta-1a 44 mcg SC 0.292 relapses/participant year of treatment (95% CI 0.235 to 0.361) | Ocrelizumab 0.156 relapses/participant year of treatment (95% CI 0.122 to 0.2) | |
| Ocrevus Zunovo | Approved | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT02792231: Annualized Relapse Rate (ASCLEPIOS II): 0.10 (ofatumumab) vs 0.25 (teriflunomide); difference -0.15 (95% CI: -0.20, -0.09) NCT02792218: Annualized relapse rate (median 1.6-year follow-up): 0.11 ofatumumab vs 0.22 teriflunomide; difference -0.11 (95% CI -0.16 to -0.06). | |
| Ozanimod (Zeposia) | Approved | Small molecule | S1P receptor | Partial signal | NCT02047734: Adjusted annualized relapse rate (ARR) over 24 months (RADIANCE): 0.17 ozanimod 1.0mg, 0.22 ozanimod 0.5mg, vs 0.28 interferon beta-1a; rate ratio vs interferon 0.62 (p<0.0001) for the 1.0mg dose and 0.79 (p=0.0167) for the 0.5mg dose NCT02294058: Adjusted Annualized Relapse Rate (ARR) During the Treatment Period (12 months): Ozanimod 0.5 mg 0.241 relapses/year (95% CI 0.188 to 0.308) | Ozanimod 1 mg 0.181 relapses/year (95% CI 0.14 to 0.236) vs Interferon Beta-1a 0.35 relapses/year (95% CI 0.279 to 0.44) | |
| Peginterferon Beta-1a (Plegridy) | Approved | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | Reliable signal | NCT00906399: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) NCT01939002: New or increased FLS during the first 8 weeks: 10.3% overall versus 25% null (p<0.0001); current FLS therapy 13% versus naproxen 7.4% (p=0.2037). | |
| Ponesimod | Approved | Small molecule | S1P receptor | Reliable signal | NCT02425644: Annualized relapse rate at week 108: 0.202 ponesimod vs 0.290 teriflunomide; rate ratio 0.695 (99% CI 0.536-0.902); 30.5% relative reduction; P<.001. | |
| Rebif (interferon Beta 1a) | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Weak signal | Featured results are non-efficacy only in this race | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | Weak signal | Featured results are non-efficacy only in this race | |
| Siponimod (Mayzent) | Approved | Small molecule | S1P receptor | Weak signal | NCT01665144: EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). | |
| Tascenso ODT | Approved | Small molecule | S1P receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Teriflunomide HMR1726 (Aubagio) | Approved | Small molecule | Dihydroorotate dehydrogenase (DHODH) | Reliable signal | NCT03122652: Time to first clinical demyelinating event: unadjusted HR 0.37 (95% CI 0.16-0.84; P=.02), adjusted HR 0.28 (95% CI 0.11-0.71; P=.007), teriflunomide vs placebo (63% unadjusted / 72% adjusted risk reduction) NCT00751881: Annualized relapse rate (core period): placebo 0.501, teriflunomide 7 mg 0.389 (relative reduction 22.3%, p=0.0183), 14 mg 0.319 (relative reduction 36.3%, p=0.0001); step-down testing, 14 mg first (CT.gov posted results). | |
| Tyruko (natalizumab-Sztn) | Approved | Monoclonal antibody | α4 integrin | not yet graded | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved | Monoclonal antibody | CD20 | Reliable signal | NCT03277248: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.091 relapses per participant-years (95% CI 0.049 to 0.169) vs Teriflunomide + IV Placebo 0.178 relapses per participant-years (95% CI 0.109 to 0.291) NCT03277261: Annualized Relapse Rate (ARR) (Up to 96 weeks): Ublituximab + Oral Placebo 0.076 relapses per participant-years (95% CI 0.042 to 0.138) | Teriflunomide + IV Placebo 0.188 relapses per participant-years (95% CI 0.124 to 0.283) | |
| ABP 692 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Dimethyl Fumarate (Skilarence) | Phase 3(overall) | Small molecule | Nrf2 pathway (fumaric acid ester) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3 | Monoclonal antibody | CD20 | Reliable signal | NCT05385744: Annualised relapse rate over 2 years (100 weeks): divozilimab 0.057 vs teriflunomide 0.164 | |
| Fenebrutinib | Phase 3 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Frexalimab | Phase 3 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | not yet graded | No reviewed efficacy summary in this indication | |
| Nabiximols (Sativex) | Phase 3 | Botanical | Cannabinoid CB1/CB2 receptors (agonist) | Partial signal | NCT04657666: Change From Baseline in Lower Limb Muscle Tone-6 (LLMT-6) (Baseline (predose Day 1 of Treatment Period 1) up to Day 51 (end of treatment of Treatment Period 2)): Nabiximols -0.23 units on a scale (Standard Error 0.07) vs Placebo -0.26 units on a scale (Standard Error 0.07) missed NCT01610700: Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment (baseline and 6 weeks): GW-1000-02 -25.32 units on a scale (Standard Deviation 23.42) vs Placebo -19.32 units on a scale (Standard Deviation 27.02) missed | |
| Remibrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | not yet graded | No reviewed efficacy summary in this indication | |
| Tolebrutinib | Phase 3 | Small molecule | Bruton's tyrosine kinase (BTK) | Reliable signal | NCT04411641: HERCULES (n=1,131, nrSPMS), primary endpoint time to onset of 6-month confirmed disability progression on EDSS: tolebrutinib 60 mg vs placebo HR 0.693 (95% CI 0.546 to 0.880), Cox regression p=0.0026 (CT.gov posted results). NCT04458051: 6-month composite confirmed disability progression (cCDP), tolebrutinib vs placebo: HR 1.01 (95% CI 0.81-1.26), p=.94 — no difference from placebo. missed | |
| Vidofludimus Calcium | Phase 3 | — | Dihydroorotate dehydrogenase (DHODH) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | Partial signal | NCT04626921: LCLA (Best-Corrected Low-Contrast Letter Acuity) change across both eyes at Week 144 vs original randomization baseline, CNM-Au8 arm: least-squares mean difference +8.70 letters (SE 1.88), 95% CI 5.0 to 12.4, p<0.0001 | |
| Corubrutinib | Phase 2 | Small molecule | Bruton's tyrosine kinase (BTK) | Partial signal | NCT05798520: Biogen reported that BIIB091 achieved proof-of-concept in relapsing-remitting MS (no figures released) | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Irafamdastat | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| A-005 | Phase 1(overall) | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Azercabtagene Zapreleucel | Phase 1(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| IDP-023 | Phase 1 | Cell therapy | Allogeneic g-NK cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| RG6035 | —(overall) | Monoclonal antibody | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6182 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Baminercept | Discontinued | Protein / enzyme therapeutic | Lymphotoxin-beta receptor (LTβR) | not yet graded | No reviewed efficacy summary in this indication | |
| Firategrast (SB-683699) | Discontinued | Small molecule | VLA-4 (integrin alpha-4/beta-1), Integrin alpha-4 (ITGA4) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Vumerity (Diroximel fumarate) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.